MA29221B1 - Ligands ameliorant des composants endogenes - Google Patents
Ligands ameliorant des composants endogenesInfo
- Publication number
- MA29221B1 MA29221B1 MA29969A MA29969A MA29221B1 MA 29221 B1 MA29221 B1 MA 29221B1 MA 29969 A MA29969 A MA 29969A MA 29969 A MA29969 A MA 29969A MA 29221 B1 MA29221 B1 MA 29221B1
- Authority
- MA
- Morocco
- Prior art keywords
- compound
- target
- ligand
- ligands
- endogenous components
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'INVENTION SE RAPPORTE À DES LIGANDS QUI COMPRENNENT UNE FRACTION (PAR EX. : DAB) COMPORTANT UN SITE DE LIAISON PRÉSENTANT UNE SPÉCIFICITÉ DE LIAISON POUR UN COMPOSÉ ENDOGÈNE CIBLE, MAIS QUI N'INHIBENT SENSIBLEMENT PAS L'ACTIVITÉ DE CE COMPOSÉ ENDOGÈNE CIBLE. DE PRÉFÉRENCE, LE LIGAND NE SE LIE PAS AU SITE ACTIF D'UN COMPOSÉ ENDOGÈNE CIBLE. CETTE INVENTION CONCERNE EN OUTRE L'UTILISATION D'UN TEL LIGAND POUR PRODUIRE UN MÉDICAMENT SERVANT À AUGMENTER LA DEMI-VIE, LA BIODISPONIBILITÉ, L'ACTIVITÉ, OU LA QUANTITÉ D'UN COMPOSÉ ENDOGÈNE CIBLE AUQUEL LE LIGAND SE LIE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/985,847 US20060002935A1 (en) | 2002-06-28 | 2004-11-10 | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29221B1 true MA29221B1 (fr) | 2008-02-01 |
Family
ID=36282598
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA29876A MA29427B1 (fr) | 2004-10-08 | 2007-05-07 | Antagonistes et leurs methodes d'utilisation |
MA29969A MA29221B1 (fr) | 2004-11-10 | 2007-06-06 | Ligands ameliorant des composants endogenes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA29876A MA29427B1 (fr) | 2004-10-08 | 2007-05-07 | Antagonistes et leurs methodes d'utilisation |
Country Status (11)
Country | Link |
---|---|
EP (2) | EP2420251A3 (fr) |
JP (1) | JP2008519813A (fr) |
KR (2) | KR20070084069A (fr) |
CN (2) | CN101724071A (fr) |
AU (1) | AU2005303584A1 (fr) |
BR (1) | BRPI0517569A (fr) |
CA (1) | CA2587206A1 (fr) |
MA (2) | MA29427B1 (fr) |
NO (2) | NO20071788L (fr) |
RU (2) | RU2401842C2 (fr) |
WO (1) | WO2006051288A2 (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
WO2005118642A2 (fr) | 2004-06-01 | 2005-12-15 | Domantis Limited | Compositions de medicaments, fusions et conjugues |
EP1802333A2 (fr) * | 2004-09-13 | 2007-07-04 | Arrowsmith Technologies LLP | Absorption in vivo d'un ligand par des anticorps |
MX2007006602A (es) * | 2004-12-02 | 2007-12-10 | Domantis Ltd | Peptidos de dominio plad con vida media en suero aumentada debido a conjugacion con anticuerpos de dominio. |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
CN102010473A (zh) * | 2010-11-10 | 2011-04-13 | 曹鹏 | 重组胃泌酸调节素融合蛋白及其制备和应用 |
PE20141727A1 (es) | 2011-07-01 | 2014-11-26 | Ngm Biopharmaceuticals Inc | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas |
CN107361011B (zh) * | 2012-03-16 | 2021-08-27 | 瑞泽恩制药公司 | 制备表达ph敏感性免疫球蛋白序列的非人动物的方法 |
MY167814A (en) | 2012-04-19 | 2018-09-26 | Opko Biologics Ltd | Long-acting oxyntomodulin variants and methods of producing same |
BR122020018510B1 (pt) | 2012-11-20 | 2023-03-14 | Opko Biologics Ltd | Método para aumentar incrementalmente o tamanho hidrodinâmico de um fator de coagulação ativado viia |
EP3798228A1 (fr) | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions et procédés pour le traitement de troubles métaboliques et de maladies |
AU2013370404B2 (en) | 2012-12-27 | 2017-11-02 | Ngm Biopharmaceuticals, Inc. | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
RU2560699C2 (ru) * | 2013-08-02 | 2015-08-20 | федеральное государственное автономное образовательное учреждение высшего профессионального образования "Национальный исследовательский ядерный университет МИФИ" (НИЯУ МИФИ) | Способ создания наноразмерной диагностической метки на основе конъюгатов наночастиц и однодоменных антител |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
MD20170020A2 (ro) | 2014-07-30 | 2017-07-31 | Ngm Biopharmaceuticals, Inc. | Compoziţii şi metode utilizate pentru tratamentul tulburărilor metabolice |
SG11201702757YA (en) | 2014-10-23 | 2017-05-30 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
CN115043945A (zh) | 2014-10-31 | 2022-09-13 | Ngm生物制药有限公司 | 用于治疗代谢病症的组合物和方法 |
ES2893616T3 (es) | 2015-06-19 | 2022-02-09 | Opko Biologics Ltd | Factores de coagulación de acción prolongada y métodos para la producción de los mismos |
ES2871036T3 (es) | 2015-11-09 | 2021-10-28 | Ngm Biopharmaceuticals Inc | Método para el tratamiento de trastornos relacionados con ácidos biliares |
AU2017296352A1 (en) | 2016-07-11 | 2019-02-21 | Opko Biologics Ltd. | Long-acting coagulation factor VII and methods of producing same |
CN110128536A (zh) * | 2018-02-02 | 2019-08-16 | 暨南大学 | 抗肿瘤干细胞标志蛋白cd133的单域抗体及其应用 |
CN109468294A (zh) * | 2018-11-06 | 2019-03-15 | 青岛古高生物科技有限公司 | 一种血红素-GroEL复合体及其制备方法和应用 |
WO2021214501A1 (fr) | 2020-04-22 | 2021-10-28 | Genima Innovations Marketing Gmbh | Décontamination antivirale dans le tuyau d'aspiration de canal ou dans l'antichambre d'un masque respiratoire |
CN115944714B (zh) * | 2022-10-20 | 2023-12-15 | 苏州大学 | 能够同时抗白细胞介素1和肿瘤坏死因子炎症的纳米材料及其制备方法与应用 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0467416A1 (fr) * | 1983-09-01 | 1992-01-22 | Hybritech Incorporated | Compositions d'anticorps d'agents therapeutiques à période de demi-vie sérique prolongée |
SU1441787A1 (ru) | 1987-04-29 | 1990-09-23 | Институт Белка Ан Ссср | Способ получени пептидов и белков в бесклеточной системе трансл ции |
ES2056108T3 (es) * | 1987-07-07 | 1994-10-01 | Hybrisens Ltd | Empleo de interacciones anticuerpo/antigeno para proteger o modular la actividad biologica. |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
US5225540A (en) * | 1988-04-26 | 1993-07-06 | Du Pont Merck Pharmaceutical Company | Monoclonal antibodies to tissue plasminogen activator (t-pa) which prolong its functional half-life |
WO1990005785A1 (fr) | 1988-11-18 | 1990-05-31 | The Regents Of The University Of California | Procede d'incorporation sur un site specifique, d'aminoacides non naturels dans des proteines |
SU1705302A1 (ru) | 1988-12-22 | 1992-01-15 | Институт Белка Ан Ссср | Способ препаративной экспрессии генов в бесклеточной системе сопр женной транскрипции/трансл ции |
ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
CA2064754C (fr) | 1989-07-31 | 1996-06-18 | Vladimir Ivanovich Baranov | Methode de preparation de polypeptides dans un systeme de translation sans cellules |
US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
KR0185192B1 (ko) | 1989-10-05 | 1999-04-01 | 제임스 더블유. 데이비 | 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리 |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
AU8498091A (en) | 1990-08-02 | 1992-03-02 | Regents Of The University Of Colorado, The | Systematic polypeptide evolution by reverse translation |
WO1992005258A1 (fr) | 1990-09-20 | 1992-04-02 | La Trobe University | Gene encodant une enzyme de l'orge |
CA2104698A1 (fr) | 1991-02-21 | 1992-08-22 | John J. Toole | Aptameres specifiques de biomolecules et methodes de production |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
DK1589107T3 (da) | 1992-08-21 | 2010-04-26 | Univ Bruxelles | Immonuglobuliner uden lette kæder |
AU8124694A (en) | 1993-10-29 | 1995-05-22 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
GB9416721D0 (en) | 1994-08-18 | 1994-10-12 | Short Brothers Plc | A bias yarn assembly forming device |
EP0846169B1 (fr) * | 1995-08-04 | 2003-03-19 | Lek, Tovarna Farmacevtskih in Kemicnih Izdelkov, D.D. | ANTICORPS MONOCLONAUX DIRIGES CONTRE LES RECEPTEURS SOLUBLES p55 ET p75 DU FACTEUR ALPHA DE NECROSE TUMORALE TNF-ALPHA DE MEME QUE CONTRE TNF-ALPHA ET SES ANALOGUES |
ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
US5837251A (en) | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
DE69738166T2 (de) | 1996-06-27 | 2008-06-19 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Antikörpermoleküle, die spezifisch mit dem aktiven Zentrum oder dem aktiven Spalt eines Zielmoleküls interagieren |
WO1998058965A2 (fr) | 1997-06-20 | 1998-12-30 | Innogenetics N.V. | Molecules de liaison avec b7 destinees au traitement d'affections immunitaires |
DE69826697T2 (de) | 1997-07-07 | 2006-02-16 | Medical Research Council | In vitro selektionsmethode |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
EP1027439B1 (fr) | 1997-10-27 | 2010-03-17 | Bac Ip B.V. | Proteines multivalentes de fixation de l'antigene |
EP1051493A2 (fr) | 1998-01-26 | 2000-11-15 | Unilever Plc | Procede servant a preparer des fragments d'anticorps |
EP1002861A1 (fr) | 1998-10-26 | 2000-05-24 | Unilever Plc | Protéines se liant aux antigènes comprenant un liant conférant une flexibilité conformationnelle limitée |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
GB9900298D0 (en) | 1999-01-07 | 1999-02-24 | Medical Res Council | Optical sorting method |
AU2291700A (en) | 1999-01-19 | 2000-08-07 | Unilever Plc | Method for producing antibody fragments |
WO2000065067A2 (fr) | 1999-04-23 | 2000-11-02 | University Of Washington | Polynucleotides, polypeptides specifiques a la prostate, et leurs procedes d'utilisation |
CA2372198A1 (fr) | 1999-05-14 | 2000-11-23 | Medical Research Council | Echafaudage proteinique interne et utilisation de ce dernier pour multimeriser des polypeptides monomeres |
WO2001040310A2 (fr) | 1999-11-29 | 2001-06-07 | Unilever Plc | Immobilisation de proteines |
WO2001058953A2 (fr) * | 2000-02-11 | 2001-08-16 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Identification d"un nouveau domaine dans la famille des recepteurs du facteur de necrose tumorale mediant l"assemblage et la fonction du recepteur de pre-ligand |
ES2324280T3 (es) | 2000-03-14 | 2009-08-04 | Unilever N.V. | Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos. |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
WO2004058821A2 (fr) * | 2002-12-27 | 2004-07-15 | Domantis Limited | Ligand |
US6608742B2 (en) | 2001-07-06 | 2003-08-19 | Schweitzer Engineering Laboratories, Inc. | Voltage and current source selection system for use in the protection, automation and control of an electric power system |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
DE10160133A1 (de) | 2001-12-07 | 2003-06-26 | Transmit Technologietransfer | Verwendung von koagulationsaktivem Antithrombin III zur Therapie von Angiogenese-abhängigen Erkrankungen |
AU2002358959A1 (en) | 2001-12-11 | 2003-07-09 | Majorem Ltd. | Massive multiplayer real-time persistant network game engine |
AU2003210806A1 (en) | 2002-03-05 | 2003-09-22 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
WO2004001064A2 (fr) * | 2002-06-21 | 2003-12-31 | Dyax Corporation | Ligands propres a un cible et associes a une proteine serique et procede d'identification correspondant |
US20060002935A1 (en) * | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
ATE328906T1 (de) * | 2002-06-28 | 2006-06-15 | Domantis Ltd | Dual-specifische liganden mit erhöhter halbwertszeit |
EP1527346B1 (fr) | 2002-08-07 | 2011-06-08 | Ablynx N.V. | Modulation de l'adhesion plaquettaire basee sur la surface exposee de la boucle beta-switch de la glycoproteine plaquettaire ib-alpha |
EP3299393A1 (fr) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Anticorps à domaine unique dirigés contre le facteur alpha de la nécrose tumorale et leurs utilisations |
US6683132B1 (en) | 2002-12-19 | 2004-01-27 | Eastman Chemical Company | Self-crosslinking aqueous acetoacetate-functionalized sulfonated alkyd systems |
RU2357974C2 (ru) | 2003-01-10 | 2009-06-10 | Аблинкс Н.В. | Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами |
EP2357237A1 (fr) | 2003-05-14 | 2011-08-17 | Domantis Limited | Un procédé pour obtenir des polypeptides qui se replient d'une manière réversible à partir d'u nrépertoire de polypeptides. |
ATE414106T1 (de) | 2003-06-30 | 2008-11-15 | Domantis Ltd | Pegylierte single-domain-antikörper (dab) |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
ATE485307T1 (de) | 2003-11-07 | 2010-11-15 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
HUE027902T2 (en) | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
US20070202099A1 (en) * | 2004-03-30 | 2007-08-30 | Hiroshi Inooka | Antibody Drug |
-
2005
- 2005-10-07 CN CN200910246166A patent/CN101724071A/zh active Pending
- 2005-10-07 KR KR1020077010453A patent/KR20070084069A/ko not_active Application Discontinuation
- 2005-10-07 RU RU2007112509/10A patent/RU2401842C2/ru not_active IP Right Cessation
- 2005-11-10 CA CA002587206A patent/CA2587206A1/fr not_active Abandoned
- 2005-11-10 AU AU2005303584A patent/AU2005303584A1/en not_active Abandoned
- 2005-11-10 KR KR1020077012946A patent/KR20070089930A/ko not_active Application Discontinuation
- 2005-11-10 WO PCT/GB2005/004319 patent/WO2006051288A2/fr active Application Filing
- 2005-11-10 EP EP11161978A patent/EP2420251A3/fr not_active Withdrawn
- 2005-11-10 JP JP2007540709A patent/JP2008519813A/ja active Pending
- 2005-11-10 EP EP05801585A patent/EP1814584A2/fr not_active Ceased
- 2005-11-10 BR BRPI0517569-0A patent/BRPI0517569A/pt not_active IP Right Cessation
- 2005-11-10 RU RU2007117196/13A patent/RU2007117196A/ru not_active Application Discontinuation
- 2005-11-10 CN CNA2005800461844A patent/CN101098712A/zh active Pending
-
2007
- 2007-04-03 NO NO20071788A patent/NO20071788L/no not_active Application Discontinuation
- 2007-05-07 MA MA29876A patent/MA29427B1/fr unknown
- 2007-05-16 NO NO20072475A patent/NO20072475L/no not_active Application Discontinuation
- 2007-06-06 MA MA29969A patent/MA29221B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
RU2401842C2 (ru) | 2010-10-20 |
RU2007117196A (ru) | 2008-12-20 |
BRPI0517569A (pt) | 2008-10-14 |
AU2005303584A1 (en) | 2006-05-18 |
EP2420251A2 (fr) | 2012-02-22 |
EP2420251A3 (fr) | 2013-03-13 |
CA2587206A1 (fr) | 2006-05-18 |
MA29427B1 (fr) | 2008-05-02 |
NO20071788L (no) | 2007-07-06 |
KR20070084069A (ko) | 2007-08-24 |
CN101724071A (zh) | 2010-06-09 |
JP2008519813A (ja) | 2008-06-12 |
EP1814584A2 (fr) | 2007-08-08 |
WO2006051288A3 (fr) | 2006-08-17 |
CN101098712A (zh) | 2008-01-02 |
NO20072475L (no) | 2007-08-06 |
RU2007112509A (ru) | 2008-11-27 |
KR20070089930A (ko) | 2007-09-04 |
WO2006051288A2 (fr) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29221B1 (fr) | Ligands ameliorant des composants endogenes | |
Otsuka et al. | Interaction of mRNAs for angiotensin II type 1 and type 2 receptors to vascular remodeling in spontaneously hypertensive rats | |
EA200301232A1 (ru) | Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы | |
MA33339B1 (fr) | Utilisation d'un anticorps anti-tau ps422 pour le traitement de maladies cérébrales | |
TNSN06358A1 (fr) | Methyl-aryl-ou-heteroaryl-amides substitues | |
TNSN06075A1 (fr) | Phenyl-ou pyridylamides servant d'antagonistes de la prostaglandine e2 | |
MA30906B1 (fr) | Composes et compositions en tant quinhibiteurs des proteines kinases | |
MA31254B1 (fr) | Anticorps contre erbb3 et leur utilisation | |
DE69920757D1 (de) | Immunsuppressive wirkungen von pteridinderivaten | |
EA199900239A1 (ru) | Замещенные n-[аминоиминометил или аминометил) фенил] пропиламиды | |
TR200102799T2 (tr) | Kemokin alıcı bağlayıcı heterosiklik bileşikler | |
BRPI0515532A (pt) | composto, composição farmacêutica, métodos de inibir a ligação de ligandos endógenos ao receptor de crth-2 em uma célula, de tratar, melhorar ou prevenir um distúrbio responsivo à inibição da ligação de ligandos endógenos ao receptor de crt-2 e de preparar um composto, e, kit | |
BR9714390A (pt) | Combinações de substâncias ativas fungicidas | |
EA200100579A1 (ru) | Хинолиновые и хиноксалиновые соединения в качестве ингибиторов pdgf-рецептора и/или тирозинкиназы lck | |
PT1214600E (pt) | Determinacao de proteinas de ligacao a adrenomedulina | |
CL2004000366A1 (es) | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. | |
EA200702110A1 (ru) | Ингибитор bcrp/abcg2 | |
MA38295B1 (fr) | Dérivé d'azole et de benzène | |
Vanholder et al. | The uraemic syndrome | |
EP1864649A3 (fr) | Composé de type bis-urée, composition le comprenant, utilisation et procédé de traitement cosmétique | |
WO2006134174A3 (fr) | Composes fviia dimeres et multimeres | |
DE60141636D1 (de) | Phospholipidderivate von valproinsäure und ihre kombinationen | |
ATE311388T1 (de) | Pyrimidotriazine als phosphataseinhibitoren | |
FR3112547B1 (fr) | Composés capables de se lier à des protéines et conjugués obtenus à partir de ces composés | |
DE60217854D1 (de) | Herstellung von agonisten und antagonisten von cholecystokinin und ihre therapeutische und diagnostische verwendung |